



ASX ANNOUNCEMENT

5 June 2024

Role of CEO Update

5 June 2024 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**), further to the Company's announcement 21 March 2024 regarding the resignation of Chief Executive Officer, Peter Koetsier, Cann today announces that Peter's last day of employment with the Company was 4 June 2024. The Company is in the process of formalising an employment agreement for the role of CEO with Ms Jenni Pilcher who has been assuming an Executive Director role in the Company.

Authorised for release by the Board of Directors of Cann Group Limited.

For all media enquiries please contact:

Jenni Pilcher
Executive Director
+61 3 9095 7088
contact@canngrouplimited.com

For all other information please contact:

Steven Notaro
Head of Legal & Regulatory Affairs and
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouplimited.com | www.satipharm.com